Eli Lilly (LLY) shares have reached approximately $1,120, which is about 13% lower than their peak in August. This price drop raises questions about buying opportunities at this level. Historical performance of stocks after significant declines shows that returning to an upward trend usually takes time and may take more than a year.
History of Stock Movements
Since 2010, Eli Lilly has only experienced three instances of a 20% decline within a 30-day period. These events occurred over a nine-month span from November 2024 to August 2025. Due to the overlap of these events, the average recovery of 48% indicates a continuous recovery cycle rather than three separate historical tests. Additionally, given the low number of these events, this data may provide a weak basis for predicting the future.
Read more: Decline in indices and the 10-year Treasury rate reaching 5% following the rise in oil prices
Analysis of Current Situation
Buyers during these periods typically face an average decline of 13% after the drop, with an average recovery time to peak of 333 days. This trend indicates that patience and perseverance are key for investors. Eli Lilly had a 49.6% revenue growth last year, reaching $79.67 billion, with 35.3% of that converting to operating cash flow. This growth reflects the company's strength in market conditions.
However, the price drop in the United States is projected at 3% in the second quarter of 2026 and 9% considering changes related to discounts and estimates. The GLP-1 Medicare program, which has been in effect since July 1, offers 20 million eligible Americans obesity medication coverage at $50 per month.
Two supportive factors for market entry exist: strong growth continues, and a new drug called Retagride is being prepared for market release in the United States in the first quarter of 2027. On the other hand, the 13% decline in shares is less than the 20% declines seen in the past, and Eli Lilly shares are currently trading at a price-to-earnings ratio of about 39 compared to 23 for the S&P 500.
The next earnings report is expected to be released around October 29, 2026, and attention to U.S. prices without significant discount changes will be important.
Read more: Sales of AI-related debt reached nearly $500 billion · Alliance Entertainment stock growth after financial results for 2026
